What type of study is this?

Nivolumab-induced vitiligo in a patient treated for metastatic melanoma

View Full Paper

Ask AI

Bookmark

Authors

Case report highlights immune checkpoint inhibitors' role in melanoma treatment, suggesting vitiligo may indicate better outcomes.

Developing vitiligo during nivolumab treatment serves as a potential positive predictor for improved melanoma outcomes.
The 37-year-old female patient displayed hypopigmented patches, indicating immune-mediated adverse effects of nivolumab.
Cytotoxic T lymphocytes likely trigger vitiligo by attacking normal melanocytes through shared antigens with melanoma.
Emergence of immunotherapy-induced vitiligo may correlate with enhanced survival rates and response to treatment in melanoma patients.

Malhan et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark